Navigation Links
BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Date:1/10/2008

ity and his M.D. from the University of California, San Diego. He completed his fellowship in gastroenterology at the University of Colorado and received his M.B.A. from the Wharton School of Business at the University of Pennsylvania. He is the author of numerous clinical and scientific publications and has secured five patents.

Dr. James Alexander will assume the role of Vice President Clinical Development reporting to Dr. Simon.

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with res
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. Medpace Strengthens Presence in Central Europe
5. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
6. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
7. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. Anavex strengthens Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... York, May 26, 2012 Sanofi ... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today ... trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients ... subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase ...
... decades, neurologists have known that a diet high in fat ... resist drug therapy. But how the diet worked, and why, ... York Times Magazine called it "Epilepsy,s Big, Fat Miracle." ... School have proposed an answer, linking resistance to seizures to ...
... growth of crystals, do nanoparticles act as "artificial atoms" ... structures? This is the contention of a major but ... researchers at the U.S. Department of Energy (DOE),s Lawrence ... and point the way to energy devices of the ...
Cached Biology Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3Nanoparticles seen as artificial atoms 2Nanoparticles seen as artificial atoms 3
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... its altitude, ozone can be either friend or foe. ... scientists will now have a better understanding of ozone, its origin ... polluting our atmosphere. Ozone is a colourless, toxic gas named ... In the stratosphere, acting as friend, ...
... wildflower, grows from the Mississippi River to Arizona and ... plant can be seen covering large areas of plains, ... Working to create a new drought-resistant and water-saving ... and Soil Science have introduced ,Raider Amethyst, a new ...
... a page from Nature herself, a team of researchers ... from the atmosphere and place it in the Earth,s ... the new technology does not make the oceans more ... process is a manipulation of the natural weathering of ...
Cached Biology News:Ozone intrusions -- humankind's fault? 2Scientists enhance Mother Nature's carbon handling mechanism 2
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: